pharmaphorum2d
Novo Nordisk tackles supply issues with $11bn Catalent deal
Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...
pharmaphorum2d
Lawmaker asks FTC to probe Novo/Catalent deal
US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give Novo Nordisk control of manufacturing facilities currently operated by ...
Nasdaq4d
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
Novo Nordisk NVO shares have lost 21% in the past ... primarily driven by increased sales of Wegovy and Ozempic. The closing of the Catalent deal in December last year is also expected to help ...
Zacks Investment Research on MSN4d
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...
Thermo Fisher Scientific Inc. (TMO) TD Cowen 45th Annual Health Care Conference - (Transcript)
Well, welcome to the 45th Annual TD Cowen Healthcare Conference. I'm Dan Brennan, follow Tools and Diagnostics. Really pleased to be joined on stage here with Marc Casper, Chairman and President of ...
Global Microbial Fermentation Technology Market To Increase At A Steady Growth Rate Of ~5% By 2032 | Delveinsight
The microbial fermentation technology market is experiencing significant growth, fueled by the increasing incidence of chronic diseases like cancer a ...
AbbVie Steps Into The Ring In The Obesity Drug Wars
AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...
ROSEN, A LEADING AND RANKED FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
New York, New York-- (Newsfile Corp. - March 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, ...
Novo Nordisk to explore how GLP-1 drugs can help patients with addiction
Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...
Why Novo Nordisk Stock Outpaced the Market Today and Hims & Hers Lagged It
Novo Nordisk 's ( NVO 3.84%) latest move in the retail sphere was met with approval from market participants Wednesday. They bid the stock up by nearly 4% following the company's news, a performance ...
South African watchdog probes Novo Nordisk and Sanofi over insulin
South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...
The Motley Fool4d
Down 39%. Is Novo Nordisk Stock a Buy on the Dip?
Novo Nordisk stock has fallen roughly 40% from a peak it reached last June. The U.S. Food and Drug Administration recently confirmed Novo Nordisk is producing enough Ozempic and Wegovy to meet demand.